Navigation Links
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
Date:9/25/2008

mplete an ongoing Phase I single dose trial to evaluate the analgesic effect of NGX426, the oral version of tezampanel, in a capsaicin model of hyperalgesia. This trial will provide data related to the onset, magnitude and duration of effect of NGX426 and will help guide the direction of the NGX426 Phase II program. In addition, the company will initiate a Phase I multiple dose trial of NGX426 to provide a platform for conducting chronic dosing clinical trials.

-- Complete an ongoing Phase II trial of NGX267 in xerostomia, or dry mouth, secondary to Sjogren's syndrome. The company has demonstrated the safety of single and multiple doses of NGX267, a muscarinic agonist, in three Phase I trials involving healthy volunteers.

-- Complete the shut down of its discovery operations in connection with the planned conclusion on September 30, 2008 of the Alzheimer's disease genetics collaboration with Eisai Co., Ltd.

TorreyPines will continue to actively seek a development partner for its clinical compounds: tezampanel, NGX426 and NGX267. In addition, the company will look to monetize its gamma-secretase modulator (GSM) and Alzheimer's disease genetics programs, as well as its compounds: phenserine, Posiphen(TM) and bisnorcymserine.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at '/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Look inside ... hard-working items for the lab, from fluid handling to ... (GIS)—ready to ship when you order. , Preferred ... Pumps , from the L/S® model for precise flow ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... be challenged by the intervention of California Governor Arnold ... Bush administration, whose campaign he supports, Schwarzenegger announced on ... Proposition 71 , a California initiative on the ... the sale of $3 billion in bonds, and lay ...
... owns worldwide make batteries, lights and personal grooming products, ... other products. The company employs about 5,000 people. Ben ... engineer Mike Gutknecht; Brent Leland, director of business IT; ... effect of Sarbanes-Oxley on IT processes, myths about ROI ...
... in Wisconsin Rapids, will lead an interstate effort to ... Governor Jim Doyle has announced. , ,The college will ... National Science Foundation, some of which will fund a ... money will also help launch a national training network ...
Cached Biology Technology:Stem-cell support from Schwarzenegger could shake Wisconsin leadership 2Stem-cell support from Schwarzenegger could shake Wisconsin leadership 3Stem-cell support from Schwarzenegger could shake Wisconsin leadership 4Rayovacs IT team discusses network security, Sarbanes-Oxley and ROI myths 2Rayovacs IT team discusses network security, Sarbanes-Oxley and ROI myths 3Rayovacs IT team discusses network security, Sarbanes-Oxley and ROI myths 4Rayovacs IT team discusses network security, Sarbanes-Oxley and ROI myths 5Wisconsin to train tech-savvy paper industry with share of $5 million grant 2
(Date:4/23/2014)... A biomedical engineer at the University of Houston ... make blood transfusions safer. His work is supported by ... Health (NIH). , Blood transfusions save millions of ... absolute necessities. Without them, for instance, routine surgeries would ... however. There,s strong evidence that transfusions of red blood ...
(Date:4/23/2014)... used to read quickly. It involves visual searching ... and/ or sentences. Similarly to humans, biological systems ... genetic information. Genes that need to be read ... encoding message, the easier it will be to ... de Cincia (IGC, Portugal) and Centre for Molecular ...
(Date:4/23/2014)... one can argue that if we were to follow a ... we canthen we can solve the climate problem without doing ... climate researchers, in the current issue of Bulletin of ... significant action on climate change now makes it more likely ... Wigley explains in an exclusive Bulletin interview. ...
Breaking Biology News(10 mins):UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Cell division speed influences gene architecture 2Is nuclear power the only way to avoid geoengineering? 2
... fundamental building block of nearly all living material: carbon. ... for bacteria. Methane is produced in oxygen-free environments and ... The Brazilian post-doctoral researcher in biology and ecology, Angela ... lakebeds to be present in fish tissue. The study ...
... This release is available in German . Vitamin ... cells and the functioning of the nervous system. Unable to produce ... animal proteins. So far it has been known that on its ... so-called lysosomes. From there, the vitamin enters the cell interior with ...
... CITY, MOTwo opposing teams battle it out to regulate ... activators, keeps DNA open to enzymes that transcribe DNA ... twisting DNA into an inaccessible coil around histone proteins, ... by enzymes that elongate an RNA strand. Both ...
Cached Biology News:How methane becomes fish food 2Vitamin B12 deficiency: Tracing the causes 2Controlling gene expression: How chromatin remodelers block a histone pass 2Controlling gene expression: How chromatin remodelers block a histone pass 3
Human peripheral blood basophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
... has been developed specifically for the ... on microwell plates/strips. Coating Stabilizer ... the antibody or protein antigen portion ... Product is filtered at 0.2 microns., ...
Biology Products: